Abstract

Our objective was to describe the duration of antibiotic therapy for the management of common outpatient conditions. The median duration of antibiotic courses for most common conditions, except for acute cystitis, was 10 days, in many cases exceeding guideline-recommended durations.

Using minimum effective antibiotic therapy durations is a component of antibiotic stewardship. Streptococcal pharyngitis, sinusitis, acute otitis media (AOM), community-acquired pneumonia (CAP), skin and soft tissues infection (SSTI), and acute cystitis are common bacterial infections leading to outpatient antibiotic prescriptions [1]. When antibiotics are indicated for these conditions, recommended therapy durations vary by syndrome (Table 1, Supplementary Table 1). Although unnecessary outpatient antibiotic prescribing is common [1], few studies have examined outpatient antibiotic course durations in the United States. The objective of this study is to describe the duration of antibiotic prescriptions for pharyngitis, sinusitis, AOM, CAP, SSTI, and acute cystitis in 2017 in US outpatients.

Table 1.

Median Duration of Estimated Non-Azithromycin Antibiotics Prescribed for Common Outpatient Conditions by Condition and Population: National Disease and Therapeutic Index, 2017

Condition and PopulationGuideline-recommended Duration of Oral Antibiotic TherapyaEstimated No. of Non-Azithromycin Antibiotic Courses (95% CI)bMedian Course Duration in Days (IQR)
Pharyngitis
 Adult10 days [2]2 116 517 (1 762 606–2 470 428)10 (10–10)
 Pediatric10 days [2]4 774 913 (4 263 388–5 286 438)10 (10–10)
Sinusitis
 Adult5–7 daysc [3]5 739 038 (5 065 041–6 413 035)10 (10–10)
 Pediatric10–14 days [3]1 478 820 (1 182 136–1 775 504)10 (10–10)
Acute otitis media
 Pediatric, all10 daysd [4]6 252 288 (5 648 066–6 856 510)10 (10–10)
 Pediatric, <2 years10 daysd [4]1 822 027 (1 524 067–2 119 987)10 (10–10)
 Pediatric, ≥2 years10 days, shorter courses (5–7 days) may be appropriate for select older childrend [4]4 430 261 (3 959 364–4 901 158)10 (10–10)
Community-acquired pneumonia
 Adult≥5 days; 5 days appropriate for most patientse [5]563 790 (394 691–732 889)10 (7–10)
 PediatricNo recommendationf [6]323 798 (204 637–442 959)10 (10–10)
Cellulitis
 Adult5 daysg [7]2 471 967 (2 098 246–2 845 688)10 (7–10)
 Pediatric5 daysg [7]621 688 (466 009–777 367)10 (10–10)
Abscess
 Adult5–10 days [7]244 791 (137 974–351 608)10 (7–10)
 Pediatric5–10 days [7]86 799 (28 731–144 867)10 (10–10)
Acute cystitis
 Females 12–64 yearsVaries by agent; 1–7 days [8]3 341 905 (2 879 353–3 804 457)7 (5–7)
Condition and PopulationGuideline-recommended Duration of Oral Antibiotic TherapyaEstimated No. of Non-Azithromycin Antibiotic Courses (95% CI)bMedian Course Duration in Days (IQR)
Pharyngitis
 Adult10 days [2]2 116 517 (1 762 606–2 470 428)10 (10–10)
 Pediatric10 days [2]4 774 913 (4 263 388–5 286 438)10 (10–10)
Sinusitis
 Adult5–7 daysc [3]5 739 038 (5 065 041–6 413 035)10 (10–10)
 Pediatric10–14 days [3]1 478 820 (1 182 136–1 775 504)10 (10–10)
Acute otitis media
 Pediatric, all10 daysd [4]6 252 288 (5 648 066–6 856 510)10 (10–10)
 Pediatric, <2 years10 daysd [4]1 822 027 (1 524 067–2 119 987)10 (10–10)
 Pediatric, ≥2 years10 days, shorter courses (5–7 days) may be appropriate for select older childrend [4]4 430 261 (3 959 364–4 901 158)10 (10–10)
Community-acquired pneumonia
 Adult≥5 days; 5 days appropriate for most patientse [5]563 790 (394 691–732 889)10 (7–10)
 PediatricNo recommendationf [6]323 798 (204 637–442 959)10 (10–10)
Cellulitis
 Adult5 daysg [7]2 471 967 (2 098 246–2 845 688)10 (7–10)
 Pediatric5 daysg [7]621 688 (466 009–777 367)10 (10–10)
Abscess
 Adult5–10 days [7]244 791 (137 974–351 608)10 (7–10)
 Pediatric5–10 days [7]86 799 (28 731–144 867)10 (10–10)
Acute cystitis
 Females 12–64 yearsVaries by agent; 1–7 days [8]3 341 905 (2 879 353–3 804 457)7 (5–7)

Abbreviations: CI, confidence interval; IQR, interquartile range.

aSee Supplementary Table 1 for full recommendations.

bEstimates and 95% CIs estimated using methods appropriate for complex samples.

cPer guidelines from the Infectious Diseases Society of America, 5–7 days is recommended for patients with uncomplicated acute bacterial sinusitis without risk factors for resistance and with initial improvement after 3–5 days [3]. The American Academy of Otolaryngology–Head and Neck Surgery Foundation recommends 5–10 days of antibiotic therapy but notes that 5–7 days may be as effective with fewer side effects compared with longer courses [9].

dGuidelines note that 7 days are likely effective for children 2–5 years with mild or moderate acute otitis media and 5–7 days likely effective for children 6 years and older with mild or moderate acute otitis media [4].

eGuidelines recommend that antibiotic therapy should be continued until the patient achieves stability, for at least 5 days, with longer durations recommended for pneumonia complicated by meningitis, endocarditis, and other infection or pneumonia due to less-common pathogens (eg, Burkholderia pseudomallei, Mycobacterium tuberculosis, or endemic fungi) [5].

fNo duration recommendation. Guidelines note: “Treatment courses of 10 days have been best studied, although shorter courses may be just as effective, particularly for more mild disease managed on an outpatient basis” [6].

gWith possible extension of antibiotic therapy duration based on symptom improvement [7].

Table 1.

Median Duration of Estimated Non-Azithromycin Antibiotics Prescribed for Common Outpatient Conditions by Condition and Population: National Disease and Therapeutic Index, 2017

Condition and PopulationGuideline-recommended Duration of Oral Antibiotic TherapyaEstimated No. of Non-Azithromycin Antibiotic Courses (95% CI)bMedian Course Duration in Days (IQR)
Pharyngitis
 Adult10 days [2]2 116 517 (1 762 606–2 470 428)10 (10–10)
 Pediatric10 days [2]4 774 913 (4 263 388–5 286 438)10 (10–10)
Sinusitis
 Adult5–7 daysc [3]5 739 038 (5 065 041–6 413 035)10 (10–10)
 Pediatric10–14 days [3]1 478 820 (1 182 136–1 775 504)10 (10–10)
Acute otitis media
 Pediatric, all10 daysd [4]6 252 288 (5 648 066–6 856 510)10 (10–10)
 Pediatric, <2 years10 daysd [4]1 822 027 (1 524 067–2 119 987)10 (10–10)
 Pediatric, ≥2 years10 days, shorter courses (5–7 days) may be appropriate for select older childrend [4]4 430 261 (3 959 364–4 901 158)10 (10–10)
Community-acquired pneumonia
 Adult≥5 days; 5 days appropriate for most patientse [5]563 790 (394 691–732 889)10 (7–10)
 PediatricNo recommendationf [6]323 798 (204 637–442 959)10 (10–10)
Cellulitis
 Adult5 daysg [7]2 471 967 (2 098 246–2 845 688)10 (7–10)
 Pediatric5 daysg [7]621 688 (466 009–777 367)10 (10–10)
Abscess
 Adult5–10 days [7]244 791 (137 974–351 608)10 (7–10)
 Pediatric5–10 days [7]86 799 (28 731–144 867)10 (10–10)
Acute cystitis
 Females 12–64 yearsVaries by agent; 1–7 days [8]3 341 905 (2 879 353–3 804 457)7 (5–7)
Condition and PopulationGuideline-recommended Duration of Oral Antibiotic TherapyaEstimated No. of Non-Azithromycin Antibiotic Courses (95% CI)bMedian Course Duration in Days (IQR)
Pharyngitis
 Adult10 days [2]2 116 517 (1 762 606–2 470 428)10 (10–10)
 Pediatric10 days [2]4 774 913 (4 263 388–5 286 438)10 (10–10)
Sinusitis
 Adult5–7 daysc [3]5 739 038 (5 065 041–6 413 035)10 (10–10)
 Pediatric10–14 days [3]1 478 820 (1 182 136–1 775 504)10 (10–10)
Acute otitis media
 Pediatric, all10 daysd [4]6 252 288 (5 648 066–6 856 510)10 (10–10)
 Pediatric, <2 years10 daysd [4]1 822 027 (1 524 067–2 119 987)10 (10–10)
 Pediatric, ≥2 years10 days, shorter courses (5–7 days) may be appropriate for select older childrend [4]4 430 261 (3 959 364–4 901 158)10 (10–10)
Community-acquired pneumonia
 Adult≥5 days; 5 days appropriate for most patientse [5]563 790 (394 691–732 889)10 (7–10)
 PediatricNo recommendationf [6]323 798 (204 637–442 959)10 (10–10)
Cellulitis
 Adult5 daysg [7]2 471 967 (2 098 246–2 845 688)10 (7–10)
 Pediatric5 daysg [7]621 688 (466 009–777 367)10 (10–10)
Abscess
 Adult5–10 days [7]244 791 (137 974–351 608)10 (7–10)
 Pediatric5–10 days [7]86 799 (28 731–144 867)10 (10–10)
Acute cystitis
 Females 12–64 yearsVaries by agent; 1–7 days [8]3 341 905 (2 879 353–3 804 457)7 (5–7)

Abbreviations: CI, confidence interval; IQR, interquartile range.

aSee Supplementary Table 1 for full recommendations.

bEstimates and 95% CIs estimated using methods appropriate for complex samples.

cPer guidelines from the Infectious Diseases Society of America, 5–7 days is recommended for patients with uncomplicated acute bacterial sinusitis without risk factors for resistance and with initial improvement after 3–5 days [3]. The American Academy of Otolaryngology–Head and Neck Surgery Foundation recommends 5–10 days of antibiotic therapy but notes that 5–7 days may be as effective with fewer side effects compared with longer courses [9].

dGuidelines note that 7 days are likely effective for children 2–5 years with mild or moderate acute otitis media and 5–7 days likely effective for children 6 years and older with mild or moderate acute otitis media [4].

eGuidelines recommend that antibiotic therapy should be continued until the patient achieves stability, for at least 5 days, with longer durations recommended for pneumonia complicated by meningitis, endocarditis, and other infection or pneumonia due to less-common pathogens (eg, Burkholderia pseudomallei, Mycobacterium tuberculosis, or endemic fungi) [5].

fNo duration recommendation. Guidelines note: “Treatment courses of 10 days have been best studied, although shorter courses may be just as effective, particularly for more mild disease managed on an outpatient basis” [6].

gWith possible extension of antibiotic therapy duration based on symptom improvement [7].

METHODS

We identified antibiotic prescriptions associated with pharyngitis, sinusitis, AOM, CAP, SSTI (abscess and cellulitis), and acute cystitis from the National Disease and Therapeutic Index (NDTI; IQVIA, Plymouth Meeting, PA) 2017 dataset. The NDTI is a 2-stage stratified cluster sample of US private-practice, office-based physicians reporting quarterly on all patient visits for 2 randomly selected, consecutive workdays. Sampled visits can be projected using NDTI sampling weights to estimate all visits to private-practice, office-based physicians in specialties captured within NDTI.

In NDTI, diagnoses are recorded in a proprietary coding scheme (see Supplementary Table 2 for included NDTI diagnosis codes). For AOM, we excluded prescriptions to adults, as only pediatric treatment guidelines are available. For acute cystitis, we only included prescriptions to females aged 12–64 years without pregnancy-related diagnoses to exclude populations for which duration recommendations do not exist or are unclear. We excluded CAP visits with ceftriaxone without another antibiotic as we could not ascertain if patients returned for further treatment.

We limited our study to oral and parenteral antibiotics prescribed or administered in office visits. We excluded observations with missing patient age or antibiotic duration. We also excluded prescriptions with durations of more than 30 days (n = 5) as these may represent prophylaxis or treatment of complex illness. We excluded hospital orders, previously initiated therapies, and reported replacement medications as true duration may be uncertain. To focus on cases not requiring specialty care, we limited our sample to prescriptions attributed to the following predefined NDTI physician specialties: emergency medicine, family practice, general practice, geriatrics, internal medicine (excluding infectious diseases), osteopathic medicine (excluding surgery and obstetrics/gynecology), and pediatrics (excluding neonatal-perinatal medicine). In NDTI, diagnoses are linked directly with medications; we excluded visits with antibiotic prescriptions for multiple conditions. For visits with multiple antibiotics for 1 condition, we used the longest duration to capture total antibiotic exposure. We excluded azithromycin prescriptions because of substantially different duration recommendations for azithromycin compared with other antibiotics based on its unique pharmacokinetics. Azithromycin is typically prescribed for courses of 5 days or less; however, because of persistent drug tissue concentrations, true exposure is longer.

We used methods appropriate for complex samples and NDTI projection weights to estimate the number of antibiotic prescriptions, antibiotic therapy durations, and 95% confidence intervals (CIs) from the sampled visits. We estimated the proportions of prescriptions by course duration and median duration and interquartile range (IQR) for each condition by age group. We categorized age group as children (<18 years) and adults (≥18 years) for all conditions except for AOM and acute cystitis. For AOM, we categorized age as all children (<18 years), those 2 years and older, and those younger than 2 years to align with guideline-recommended durations. We calculated potentially excessive antibiotic days by summing the number of days above minimum recommended duration by condition (Supplementary Table 3), accounting for sampling weights. For conditions with guideline-recommended durations provided as ranges (eg, sinusitis, abscess), we used the upper-bound value as the recommended duration. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS

In 2017, there were 2889 sampled antibiotic prescriptions from visits that met our inclusion criteria, translating to a national estimate of 31 548 464 (95% CI, 29 833 606–3333 263 322) antibiotic prescriptions from private-practice, office-based physicians in the included specialties. Eleven percent (95% CI, 10–13%) of these estimated prescriptions were azithromycin, and therefore excluded from our duration analyses, leaving 28 016 314 (95% CI, 26 430 509–29 602 119) included antibiotic prescriptions.

Estimated prescription numbers, guideline-recommended durations, and median antibiotic durations for each condition and age group are presented in Table 1. Median duration was 10 days for every condition except for acute cystitis, for which median duration was 7 days (IQR, 5–7 days). Overall, 55% (95% CI, 53–58%) of nonazithromycin antibiotic courses in our study exceeded guideline-recommended minimum effective durations, translating to up to 54 496 316 potentially excessive days of therapy. Among adults, 74% (95% CI, 71–77%) of antibiotic courses exceeded minimum guideline-recommended durations, compared with 36% (95% CI, 33–39%) in children. For pharyngitis, 85% (95% CI, 79–90%) (Supplementary Figure 1) of estimated antibiotic prescriptions in adults and 97% (95% CI, 95–98%) in children were for 10 days, the guideline-recommended duration. For sinusitis, among adults, 90% (95% CI, 87–94%) of antibiotic prescriptions exceeded the guideline-recommended 5–7 days; 86% (95% CI, 82–90%) of adult antibiotic courses for sinusitis were for 10 days (Supplementary Figure 2). Almost all, 97% (95% CI, 95–100%), antibiotic prescriptions for sinusitis in children were for 10 days, in concordance with the guideline-recommendation of 10–14 days. For AOM in children younger than 2 years, 96% (95% CI, 93–99%) of prescriptions were for the recommended 10 days (Supplementary Figure 3). A similar proportion of 10-day courses was observed in children aged 2 years or older (95%; 95% CI, 93–97%). Although courses of 5–7 days or 7 days are suggested for select children aged 2 years or older with AOM [4], only 5% (95% CI, 2–7%) of prescriptions for this population were for 5–7 days. For CAP in adults, only 6% (95% CI, 0–14%) of prescriptions were for 5 days, which is the appropriate duration for most patients, according to guidelines [5] (Supplementary Figure 4). For CAP in children, for which there is no recommended duration of antibiotic therapy, 93% (95% CI, 84–100%) of prescriptions were for 10 days. For cellulitis, 99% (95% CI, 97–100%) of prescriptions to adults and 93% (95% CI, 85–100%) of prescriptions to children were for longer than 5 days, which is recommended for most patients demonstrating clinical improvement; the majority were for 10 days (Supplementary Figure 5). For abscess, 88% (95% CI, 74–100%) of prescriptions in adults and 80% (95% CI, 55–100%) of prescriptions in children were for guideline-recommended 5- to 10-day durations; all remaining antibiotic therapy durations for abscess were for 14 days or more (Supplementary Figure 6). For acute cystitis in females aged 12–64 years, duration distribution varied by agent (Supplementary Figure 7). At least 75% (95% CI, 69–81%) of antibiotic prescriptions for acute cystitis had durations longer than those recommended by guidelines, accounting for antibiotic agent.

Discussion

In our study of systemic antibiotic therapy duration, we found that clinicians defaulted to 10-day courses for most conditions, regardless of guideline recommendations. Median antibiotic course duration was 10 days for all conditions except for acute cystitis. For some conditions and age groups, such as pharyngitis, pediatric sinusitis, and pediatric AOM, 10 days of antibiotic therapy aligns with guidelines. However, for many conditions, specifically sinusitis and CAP in adults and cellulitis, 10 days of antibiotic therapy is likely excessive for most patients based on guideline recommendations. Although median antibiotic therapy duration for acute cystitis was shorter, many course durations still exceeded guideline recommendations.

Recently, the body of evidence on minimum effective antibiotic therapy duration has grown and, consequently, guidelines recommend shorter antibiotic courses for acute uncomplicated cystitis in women [8], sinusitis in adults [3, 9], CAP in adults [5], and SSTI [7] and have suggested shorter courses may be appropriate for AOM in older children with mild or moderate disease [4]. Despite updated guideline recommendations for shorter courses, many outpatients are receiving antibiotic durations that exceed guideline recommendations, perhaps driven by clinician habit. Longer antibiotic courses have been associated with increased risks of adverse events [8, 10] and antibiotic-resistant infections [6, 11], putting patients at avoidable risk. Additionally, further research and stronger recommendations on minimum effective durations, especially in children, may be needed. For example, pediatric CAP guidelines do not provide definitive duration recommendations but note that 10-day courses are best studied; however, shorter courses may be as effective [6]. Stronger evidence and explicit guidelines may empower clinicians to improve antibiotic therapy durations.

The Centers for Disease Control and Prevention’s Core Elements of Outpatient Antibiotic Stewardship [12] provides a framework for improving antibiotic use, including duration, in outpatient settings. Particularly, clinical decision support shows promise in improving guideline-concordant antibiotic therapy duration in outpatient settings [13], perhaps by reinforcing recommended antibiotic therapy durations at the time of prescribing and changing clinician defaults.

Our study has several limitations. First, we were unable to account for underlying conditions, previous treatment failures, and other factors that might warrant longer durations. Second, we limited our analysis to antibiotic duration and assumed all antibiotics prescribed were warranted, which is unlikely [1]. Third, the NDTI dataset uses proprietary methodology to estimate prescription weights and may not be nationally representative. Fourth, the NDTI dataset does not include non–private-practice physician outpatient settings, including urgent care clinics and emergency departments, where antibiotic duration patterns may vary.

We found that clinicians frequently defaulted to 10-day durations even when guidelines recommend shorter durations, potentially exposing patients to unnecessarily long antibiotic therapy durations for many common conditions. Specifically, compliance with recommended duration of antibiotic therapy could be improved for sinusitis and CAP in adults, cellulitis in all ages, and acute cystitis in women aged 12–64 years. Increased focus on appropriate duration of antibiotic therapy for these common conditions could reduce unnecessary outpatient antibiotic use.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Financial support. This work was supported by the Centers for Disease Control and Prevention.

Potential conflicts of interest. L. M. K. is a contractor employed by Northrop Grumman Corporation to fulfill research needs at the Centers for Disease Control and Prevention as part of a contract covering many positions and tasks. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1.

Fleming-Dutra
KE
,
Hersh
AL
,
Shapiro
DJ
, et al.
Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011
.
JAMA
2016
;
315
:
1864
73
.

2.

Shulman
ST
,
Bisno
AL
,
Clegg
HW
, et al. ;
Infectious Diseases Society of America
.
Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America
.
Clin Infect Dis
2012
;
55
:
e86
102
.

3.

Chow
AW
,
Benninger
MS
,
Brook
I
, et al. ;
Infectious Diseases Society of America
.
IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults
.
Clin Infect Dis
2012
;
54
:
e72
112
.

4.

Lieberthal
AS
,
Carroll
AE
,
Chonmaitree
T
, et al.
The diagnosis and management of acute otitis media
.
Pediatrics
2013
;
131
:
e964
99
.

5.

Metlay
JP
,
Waterer
GW
,
Long
AC
, et al.
Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America
.
Am J Respir Crit Care Med
2019
;
200
:
e45
67
.

6.

Bradley
JS
,
Byington
CL
,
Shah
SS
, et al. ;
Pediatric Infectious Diseases Society; Infectious Diseases Society of America
.
The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America
.
Clin Infect Dis
2011
;
53
:
e25
76
.

7.

Stevens
DL
,
Bisno
AL
,
Chambers
HF
, et al. ;
Infectious Diseases Society of America
.
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America
.
Clin Infect Dis
2014
;
59
:
e10
52
.

8.

Gupta
K
,
Hooton
TM
,
Naber
KG
, et al.
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
.
Clin Infect Dis
2011
;
52
:
e103
20
.

9.

Rosenfeld
RM
,
Nnacheta
LC
,
Corrigan
MD
.
Clinical consensus statement development manual
.
Otolaryngol Head Neck Surg
2015
;
153
:
S1
S14
.

10.

Tansarli
GS
,
Mylonakis
E
.
Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults
.
Antimicrob Agents Chemother
2018
;
62
:
e00635
18
.

11.

Gouliouris
T
,
Warne
B
,
Cartwright
EJP
, et al.
Duration of exposure to multiple antibiotics is associated with increased risk of VRE bacteraemia: a nested case-control study
.
J Antimicrob Chemother
2018
;
73
:
1692
9
.

12.

Sanchez
GV
,
Fleming-Dutra
KE
,
Roberts
RM
,
Hicks
LA
.
Core elements of outpatient antibiotic stewardship
.
MMWR Recomm Rep
2016
;
65
:
1
12
.

13.

Eudaley
ST
,
Mihm
AE
,
Higdon
R
,
Jeter
J
,
Chamberlin
SM
.
Development and implementation of a clinical decision support tool for treatment of uncomplicated urinary tract infections in a family medicine resident clinic
.
J Am Pharm Assoc (2003)
2019
;
59
:
579
85
.

This work is written by (a) US Government employee(s) and is in the public domain in the US.